Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library
出版年份 2021 全文链接
标题
Identification of non-covalent 3C-like protease inhibitors against severe acute respiratory syndrome coronavirus-2 via virtual screening of a Korean compound library
作者
关键词
Coronavirus disease 2019, Severe acute respiratory syndrome coronavirus 2, 3C-like protease, Inhibitors, Antivirals
出版物
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS
Volume 42, Issue -, Pages 128067
出版商
Elsevier BV
发表日期
2021-05-04
DOI
10.1016/j.bmcl.2021.128067
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Kinetic characterization and inhibitor screening for the proteases leading to identification of drugs against SARS-CoV-2
- (2021) Chih-Jung Kuo et al. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
- Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro
- (2020) Manli Wang et al. CELL RESEARCH
- Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
- (2020) Chaolin Huang et al. LANCET
- A Novel Coronavirus from Patients with Pneumonia in China, 2019
- (2020) Na Zhu et al. NEW ENGLAND JOURNAL OF MEDICINE
- Remdesivir is a direct-acting antiviral that inhibits RNA-dependent RNA polymerase from severe acute respiratory syndrome coronavirus 2 with high potency
- (2020) Calvin J. Gordon et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Structure of Mpro from SARS-CoV-2 and discovery of its inhibitors
- (2020) Zhenming Jin et al. NATURE
- Structural basis for the inhibition of SARS-CoV-2 main protease by antineoplastic drug carmofur
- (2020) Zhenming Jin et al. NATURE STRUCTURAL & MOLECULAR BIOLOGY
- Compassionate Use of Remdesivir for Patients with Severe Covid-19
- (2020) Jonathan Grein et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structure-based design of antiviral drug candidates targeting the SARS-CoV-2 main protease
- (2020) Wenhao Dai et al. SCIENCE
- Crystal structure of SARS-CoV-2 main protease provides a basis for design of improved α-ketoamide inhibitors
- (2020) Linlin Zhang et al. SCIENCE
- Boceprevir, GC-376, and calpain inhibitors II, XII inhibit SARS-CoV-2 viral replication by targeting the viral main protease
- (2020) Chunlong Ma et al. CELL RESEARCH
- Potential of coronavirus 3C-like protease inhibitors for the development of new anti-SARS-CoV-2 drugs: Insights from structures of protease and inhibitors
- (2020) Jun He et al. INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS
- Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing
- (2020) Laura Riva et al. NATURE
- Uncovering Flexible Active Site Conformations of SARS-CoV-2 3CL Proteases through Protease Pharmacophore Clusters and COVID-19 Drug Repurposing
- (2020) Nikhil Pathak et al. ACS Nano
- Saracatinib Inhibits Middle East Respiratory Syndrome-Coronavirus Replication In Vitro
- (2018) Jin Shin et al. Viruses-Basel
- Broad-spectrum antiviral GS-5734 inhibits both epidemic and zoonotic coronaviruses
- (2017) Timothy P. Sheahan et al. Science Translational Medicine
- An Overview of Severe Acute Respiratory Syndrome–Coronavirus (SARS-CoV) 3CL Protease Inhibitors: Peptidomimetics and Small Molecule Chemotherapy
- (2016) Thanigaimalai Pillaiyar et al. JOURNAL OF MEDICINAL CHEMISTRY
- The SARS-coronavirus papain-like protease: Structure, function and inhibition by designed antiviral compounds
- (2015) Yahira M. Báez-Santos et al. ANTIVIRAL RESEARCH
- Clusters of coronavirus cases put scientists on alert
- (2012) Declan Butler NATURE
- Isolation of a Novel Coronavirus from a Man with Pneumonia in Saudi Arabia
- (2012) Ali M. Zaki et al. NEW ENGLAND JOURNAL OF MEDICINE
- Profiling of Substrate Specificity of SARS-CoV 3CLpro
- (2010) Chi-Pang Chuck et al. PLoS One
Become a Peeref-certified reviewer
The Peeref Institute provides free reviewer training that teaches the core competencies of the academic peer review process.
Get StartedAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started